These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24499868)

  • 1. Breast tumor subgroups reveal diverse clinical prognostic power.
    Liu Z; Zhang XS; Zhang S
    Sci Rep; 2014 Feb; 4():4002. PubMed ID: 24499868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
    Baselga J; Manikhas A; Cortés J; Llombart A; Roman L; Semiglazov VF; Byakhov M; Lokanatha D; Forenza S; Goldfarb RH; Matera J; Azarnia N; Hudis CA; Rozencweig M
    Ann Oncol; 2014 Mar; 25(3):592-598. PubMed ID: 24401928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer.
    Chen F; Gao S; Wang F; Ma J; Zhang M; Lv M; Zhou Q; Fu Z; Lu C; Yin H
    Tumour Biol; 2016 Mar; 37(3):3365-70. PubMed ID: 26446459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples.
    Dvorkin-Gheva A; Hassell JA
    PLoS One; 2011; 6(10):e26023. PubMed ID: 22022496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.
    Prat A; Bianchini G; Thomas M; Belousov A; Cheang MC; Koehler A; Gómez P; Semiglazov V; Eiermann W; Tjulandin S; Byakhow M; Bermejo B; Zambetti M; Vazquez F; Gianni L; Baselga J
    Clin Cancer Res; 2014 Jan; 20(2):511-21. PubMed ID: 24443618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant chemotherapy for breast cancer and targeted therapies].
    Dufresne A; Bachelot T; Blay JY
    Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
    Hanker LC; Rody A; Holtrich U; Pusztai L; Ruckhaeberle E; Liedtke C; Ahr A; Heinrich TM; Sänger N; Becker S; Karn T
    Breast Cancer Res Treat; 2013 Jan; 137(2):407-16. PubMed ID: 23242614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
    Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
    Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
    J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
    Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
    Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
    Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
    Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
    Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
    Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma.
    Baretta Z; Guindalini RS; Khramtsova G; Olopade OI
    Clin Breast Cancer; 2013 Apr; 13(2):156-8. PubMed ID: 23276464
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.